Is ZTS a good stock to buy? We came across a bullish thesis on Zoetis Inc. on r/ValueInvesting by ringdingjinglejangle. In this article, we will summarize the bulls’ thesis on ZTS. Zoetis Inc.’s share was trading at $75.89 as of June 22nd. ZTS’s trailing and forward P/E were 12.44 and 11.10 respectively according to Yahoo Finance.
werzk-luuu-tDlo2ZPlQlU-unsplash
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for the animal health industry in the United States and internationally.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Read More: Undervalued AI Stock Poised For Massive Gains: 10000% Upside Potential
ZTS is presented as a compelling contrarian opportunity after a dramatic decline that has pushed the stock down more than 50% from its highs and compressed its valuation to roughly 12.8x trailing earnings, far below its historical average of 36.6x. The company remains the global leader in animal health, benefiting from a diversified portfolio across companion animals, livestock, therapeutics, vaccines, diagnostics, and international markets.
Companion Animal products account for approximately 70% of revenue and include market-leading franchises such as Simparica, Apoquel, and Cytopoint, while the Livestock segment provides stability and has recently delivered strong organic growth. The market’s pessimism is largely tied to weakness in Librela and Solensia, two osteoarthritis treatments that experienced declining sales following social media-driven safety concerns and softer veterinary clinic traffic. However, the thesis argues that these challenges are temporary perception issues rather than evidence of permanent franchise impairment.
Zoetis is actively educating veterinarians and reinforcing the clinical data supporting these products, creating a path toward sales stabilization and renewed investor confidence. Beyond this recovery opportunity, the company benefits from a cash-pay business model that supports consistent pricing power, allowing regular price increases without the reimbursement pressures faced by human pharmaceutical companies. As veterinary traffic normalizes, pricing and volume growth could restore high-single-digit revenue expansion.
Zoetis also generates substantial free cash flow and is aggressively returning capital through dividends and share repurchases, which become increasingly accretive at the current depressed valuation. With industry-leading margins, resilient demand, and limited generic competition, the company appears significantly undervalued. If investor sentiment normalizes and Zoetis rerates to a more conservative 25x earnings multiple, the stock could deliver nearly 100% upside from current levels.
Previously, we covered a bullish thesis on Zoetis Inc. (ZTS) by Best Anchor Stocks in December 2024, which highlighted accelerating growth driven by OA pain therapies, strong execution across companion animal franchises, and expanding market leadership. ZTS’s stock price has depreciated by approximately 53.92% since our coverage. ringdingjinglejangle shares a similar view but emphasizes valuation compression, sentiment-driven weakness, and nearly 100% upside from multiple rerating.
Zoetis Inc. is not on our list of the 40 Most Popular Stocks Among Hedge Funds. As per our database, 57 hedge fund portfolios held ZTS at the end of the first quarter which was 69 in the previous quarter. While we acknowledge the risk and potential of ZTS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ZTS and that has 10,000% upside potential, check out our report about this cheapest AI stock.
Disclosure: None.
